Related Experiment Video

Updated: Jul 4, 2026

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease

K Fujita1, Y Nozaki, K Wada

  • 1Division of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan.

Gut
|July 4, 2008
PubMed
Abstract

Insights

Antiplatelet drugs, particularly cilostazol, show promise in treating non-alcoholic fatty liver disease (NAFLD). These agents effectively reduced liver steatosis, inflammation, and fibrosis in rat models, offering a new therapeutic strategy for NAFLD.

Area of Science:

  • Hepatology
  • Pharmacology
  • Internal Medicine

Background:

  • Non-alcoholic fatty liver disease (NAFLD) lacks effective pharmacological treatments.
  • Current management strategies for NAFLD, including diet and exercise, have limitations.
  • Novel therapeutic approaches for NAFLD are urgently required.

Purpose of the Study:

  • To investigate the potential of antiplatelet agents as a novel treatment for non-alcoholic fatty liver disease (NAFLD).
  • To evaluate the efficacy of aspirin, ticlopidine, and cilostazol in mitigating NAFLD progression in preclinical models.

Main Methods:

  • Fisher 344 male rats were administered a choline-deficient, L-amino acid-defined (CDAA) diet or a high-fat, high-calorie (HF/HC) diet.
  • Rats received aspirin, ticlopidine, or cilostazol for 16 weeks to assess their impact on NAFLD.
  • Liver steatosis, inflammation, and fibrosis were analyzed, along with underlying molecular mechanisms.

Main Results:

  • Aspirin, ticlopidine, and cilostazol significantly reduced liver steatosis, inflammation, and fibrosis in rats on the CDAA diet.
  • Cilostazol demonstrated the greatest efficacy, also suppressing liver steatosis induced by the HF/HC diet.
  • Cilostazol's mechanism involves suppressing oxidative stress-induced mitogen-activated protein kinase activation.

Conclusions:

  • Antiplatelet agents, especially cilostazol, represent a promising therapeutic strategy for non-alcoholic fatty liver disease (NAFLD).
  • Cilostazol's ability to ameliorate key NAFLD pathologies warrants further clinical investigation.

More Related Videos

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...